DYRK1A and pancreatic insulinoma: Finally, we highlight that previously reported mitogenic targets of the harmine class of beta cell mitogenic drugs2–4—DYRK1A (from the red module, Fig. 2), and MYC (also upregulated in insulinomas, Supplementary Data 8) and its inhibitor, MNT (Fig. 6)—are also present in this analysis.